Trial Profile

Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms PILOT-2020-511

Most Recent Events

24 Oct 2023 Results (n=41) assessing the combination of tislelizumab plus definitive chemoradiotherapy in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy, presented at the 48th European Society for Medical Oncology Congress.
22 May 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com